Brezivaptan

Brezivaptan^[1] (developmental code names ANC-501, THY-1773, TS-121) is an orally active, selective vasopressin V_1B receptor antagonist which is under development by Taisho Pharmaceutical for the adjunctive treatment of major depressive disorder.^[2][3][4] As of November 2022, it is in phase II clinical trials for this indication.^[2][3][5]

Other namesTS-121; TS121; TS-1211; TS1211; THY1773; THY-1773; ANC-501; ANC501

Routes of
administrationBy mouth

CAS Number

• 1370444-22-6

PubChem CID

• 56952080

Quick facts Clinical data, Other names ...

Brezivaptan

Clinical data
Other names	TS-121; TS121; TS-1211; TS1211; THY1773; THY-1773; ANC-501; ANC501
Routes of administration	By mouth
Identifiers
IUPAC name 2-[3-(3-chlorophenyl)-1-[4-(2-morpholin-4-ylethyl)phenyl]-5-oxo-1,2,4-triazol-4-yl]-N-propan-2-ylacetamide
CAS Number	1370444-22-6
PubChem CID	56952080
DrugBank	DB18907
ChemSpider	129325033
UNII	575OB1CKN0
ChEMBL	ChEMBL5314910
Chemical and physical data
Formula	C25H30ClN5O3
Molar mass	484.00 g·mol−1
3D model (JSmol)	Interactive image
SMILES CC(C)NC(=O)CN1C(=NN(C1=O)C2=CC=C(C=C2)CCN3CCOCC3)C4=CC(=CC=C4)Cl
InChI InChI=1S/C25H30ClN5O3/c1-18(2)27-23(32)17-30-24(20-4-3-5-21(26)16-20)28-31(25(30)33)22-8-6-19(7-9-22)10-11-29-12-14-34-15-13-29/h3-9,16,18H,10-15,17H2,1-2H3,(H,27,32) Key:YCLGGNJZGIFVKX-UHFFFAOYSA-N

Close